Latest news with #GeneralRegulation
Business Wire
04-08-2025
- Business
- Business Wire
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
MARSEILLE, France--(BUSINESS WIRE)--Regulatory news: Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as of August 1, 2025: (1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017. (2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Business Wire
28-07-2025
- Business
- Business Wire
Verallia Announces the Success of the Voluntary Public Tender Offer Initiated by BWGI
PARIS--(BUSINESS WIRE)--Regulatory News: The initial period of the Offer initiated by BWGI, acting through Kaon V 1, on the Verallia shares that it does not already own, closed successfully on July 25, 2025. 50,097,577 Verallia's shares were tendered to the Offer during its initial period, representing 41.47% of Verallia's share capital and 34.88% of its voting rights, allowing BWGI to hold 70.31% of Verallia's share capital and 62.81% of its voting rights from the settlement-delivery of the initial Offer. BWGI, which therefore becomes the controlling shareholder of Verallia, intends to support Verallia in creating long-term value by executing its strategic plan, which places innovation and the energy transition at the heart of its project. The notice of results (avis de résultat) published by the French financial markets authority (' AMF ') is available on its website ( The settlement-delivery of the initial Offer will take place on August 1 st, 2025. Reopening of the Offer In accordance with the provisions the AMF's General Regulation, the Offer will be reopened for 10 trading days, under the same financial terms as those set out in Kaon V's offer document approved by the AMF's under number no. 25-196 on June 5, 2025 (i.e. an Offer price of €28.30 per Verallia share), in order to enable shareholders who have not tendered their shares to the initial Offer to do so during the reopened Offer if they wish to. The AMF will publish a notice related to the timetable of the reopened Offer, which will be available on its website ( The tender procedure and the centralization of the reopened Offer will be identical to those applicable to the initial Offer, it being specified, however, that tender orders to the reopened Offer will be irrevocable. The documentation relating to the Offer, including the 'other information' documents relating to the legal, financial and accounting characteristics of Kaon V and Verallia, is available on both Verallia's ( and the AMF's ( websites. D.F. King Ltd is acting as information agent for Verallia's institutional shareholders (contact: Mr. David Chase Lopes, Managing Director, EMEA, A guide for investors in the form of 'questions and answers' is available on Verallia's website ( to address questions that may be raised by shareholders. About Verallia At Verallia, our purpose is to re-imagine glass for a sustainable future. We want to redefine how glass is produced, reused and recycled, to make it the world's most sustainable packaging material. We work together with our customers, suppliers and other partners across the value chain to develop new, beneficial and sustainable solutions for all. With almost 11,000 employees and 35 glass production facilities in 12 countries, we are the European leader and world's third-largest producer of glass packaging for beverages and food products. We offer innovative, customised and environmentally friendly solutions to over 10,000 businesses worldwide. Verallia produced more than 16 billion glass bottles and jars and recorded revenue of €3.5 billion in 2024. Verallia's CSR strategy has been awarded the Ecovadis Platinum Medal, placing the Group in the top 1% of companies assessed by Ecovadis. Our CO 2 emissions reduction target of -46% on scopes 1 and 2 between 2019 and 2030 has been validated by SBTi (Science Based Targets Initiative). It is in line with the trajectory of limiting global warming to 1.5° C set by the Paris Agreement. Verallia is listed on compartment A of the regulated market of Euronext Paris (Ticker: VRLA – ISIN: FR0013447729) and trades on the following indices: CAC SBT 1.5°, STOXX600, SBF 120, CAC Mid 60, CAC Mid & Small and CAC All-Tradable. Disclaimer This press release does not constitute an offer to purchase securities or a solicitation to invest in securities in France, the United States, or any other jurisdiction. Any decision regarding the Offer must be based exclusively on the information contained in the Offer documents. This press release has been prepared for information purposes only. The distribution of this press release, the Offer and its acceptance may be subject to specific regulation or restrictions in certain countries. The Offer is not intended for persons subject to such restrictions. Consequently, persons in possession of this press release are required to inquire about any local restrictions that may apply and to comply with them. Verallia assumes no responsibility for any violation of these restrictions by anyone. Protection of personal data You may unsubscribe from the distribution list of our press releases at any time by sending your request to the following email address: investors@ Press releases will still be available via the website Verallia SA, as data controller, processes personal data for the purpose of implementing and managing its internal and external communication. This processing is based on legitimate interests. The data collected (last name, first name, professional contact details, profiles, relationship history) is essential for this processing and is used by the relevant departments of the Verallia Group and, where applicable, its subcontractors. Verallia SA transfers personal data to its service providers located outside the European Union, who are responsible for providing and managing technical solutions related to the aforementioned processing. Verallia SA ensures that the appropriate guarantees are obtained in order to supervise these data transfers outside of the European Union. Under the conditions defined by the applicable regulations for the protection of personal data, you may access and obtain a copy of the data concerning you, object to the processing of this data and request for it to be rectified or erased. You also have a right to restrict the processing of your data. To exercise any of these rights, please contact the Group Financial Communication Department at investors@ If, after having contacted us, you believe that your rights have not been respected or that the processing does not comply with data protection regulations, you may submit a complaint to the CNIL (Commission nationale de l'informatique et des libertés — France's regulatory body). 1 BWGI is acting as the investment manager of Kaon V, a sub-fund of Kaon Investment Fund ICAV and direct shareholder of Verallia.
Yahoo
24-07-2025
- Business
- Yahoo
LECTRA: Second Quarter and First Half 2025 financial report available
Second Quarter and First Half 2025 financial report available Paris, July 24, 2025 – Lectra informs its shareholders, in compliance with Article 221-4-IV of the General Regulation of the Autorité des marchés financiers, that the Management Discussion and Analysis of Financial Condition and Results of Operations for the Second Quarter and First Half of 2025 is available on the company's website: It is also available, upon request, at the company's headquarters 16-18 rue Chalgrin, 75016 Paris (email: ). Copy of this document was filed with the AMF. About Lectra : At the forefront of innovation since its founding in 1973, Lectra provides industrial intelligence technology solutions—combining software in SaaS mode, cutting equipment, data, and associated services—to players in the fashion, automotive and furniture industries. With boldness and passion, Lectra accelerates the transformation and success of its customers in a world in perpetual motion thanks to the key technologies of Industry 4.0: AI, big data, cloud and the Internet of Things. The Group is present in more than one hundred countries. It operates three production sites for its cutting equipment, located in France, China and the United States. Lectra's 3,000 employees are driven by three core values: being open-minded thinkers, trusted partners and passionate innovators. They all share the same concern for social responsibility, which is one of the pillars of Lectra's strategy to ensure its sustainable growth and that of its customers. Lectra reported revenues of €527 million in 2024, including €77 million coming from its SaaS offerings. The company is listed on Euronext, and is included in the CAC All Shares, CAC Technology, EN Tech Leaders and ENT PEA-PME 150 indices. For more information, please visit Lectra – World Headquarters et siège social : 16–18, rue Chalgrin • 75016 Paris • France Tél. +33 (0)1 53 64 42 00 – Société anonyme au capital de 37 966 274 €. RCS Paris B 300 702 305 Attachment LECTRA_PR_reportavailable_FH2025Sign in to access your portfolio
Business Wire
11-07-2025
- Business
- Business Wire
Number of Shares and Voting Rights of ADOCIA as of June 30 th, 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French 'Code de Commerce' and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or 'AMF'), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of June 30 th, 2025. * 192,300 free shares have been issued during the month in accordance with the plans detailed in section 5.1.5.2 of the 2024 Universal Registration Document, released on April 29, 2025. (1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. (2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone ® technology for the development of new generation insulins and products combining different hormones; 2) AdOral ®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Business Wire
04-07-2025
- Business
- Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as of July 3, 2025: (1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017. (2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
